Business
Maricann Group: A Diversified Opportunity in the Global Cannabis Industry -- CFN Media
Maricann Group: A Diversified Opportunity in the Global Cannabis Industry -- CFN Media.
About this update from Wayland Group Corp
[{"type":"text","content":"\n\n SEATTLE, Feb. 01, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (\"CannabisFN\"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering Maricann Group Inc.'s (CSE:MARI) (CNSX:MARI) (MARI.CN) (OTCQB:MRRCF) exposure to the global cannabis market. Maricann Group is a licensed producer of medical cannabis under Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR). The company has exposure to Europe, as well as attractive competitive advantages in both medical and adult-use cannabis sectors.\n The Canadian cannabis industry is projected to reach C$22.6 billion in size over the coming years, according to Deloitte, driven by the legalization of adult-use marijuana. While most licensed producers are focused on the domestic market, the legalization of medical marijuana across much of Europe has opened the door to new opportunities. Investors may want to consider LPs focused on many areas of both Canada and Europe. Significant Production Capacity After securing a cultivation license in March of 2014, Maricann Group began selling dried cannabis in January of 2015 and extracts in October of 2016. In addition to Canada, the company’s Germany-based Ebersbach facility targets the massive European market with 820,000 sq. ft. of cultivation space and over 12,000 patients. The company has near-term plans to expand its production with a brand new, state-of-the-art facility on 100 acres of land in Ontario. During the second quarter of this year, management plans to complete the first phase of construction with 22,500 kilograms per year of capacity at a cost of $1.34 per gram. The company plans to further expand in the second half of the year to 942,000 sq. ft. of space with 95,000 kilograms per year of capacity at 60 cents per gram. Unlike many Canadian cultivation facilities, the company’s low-cost and high-efficiency facility will leverage cutting-edge robotics and automation technology to ease compliance, enhance quality, and reduce costs. This could translate to higher quality products for consumers and higher margin products for investors. Management believes that this level of automation is unparalleled in the cannabis industry and sets a new standard for quality and excellence. Recreational & Medical Focus Maricann Group has developed educ...